Tracers / [177Lu]Lu-EB-PSMA-617
[177Lu]Lu-EB-PSMA-617
Also written as [Lu-177]Lu-EB-PSMA-617; Lu-177-EB-PSMA-617
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- pilot study
- Syntheses indexed
- 1
What it is
- Compound class
- PSMA-targeting urea-based small molecule with Evans blue (albumin-binding) moiety, DOTA-chelated Lu-177 radioligand
- Target / mechanism
- PSMA (prostate-specific membrane antigen) PMID 35984529
- Clinical application
- PSMA-targeted radioligand therapy for PSMA-expressing adenoid cystic carcinoma PMID 35984529
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 35984529 2022 EJNMMI Res |
Need this precursor?We can point you to suppliers for [177Lu]Lu-EB-PSMA-617, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 35984529: 'This pilot study was designed to evaluate the diagnostic value of 68 Ga-PSMA-617 and 18F-FDG PET/CT in adenoid cystic carcinoma (ACC) and to assess the safety and therapeutic response to PSMA radioligand therapy (RLT) in ACC patients.'.